Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

J. K. Hicks; J. R. Bishop; K. Sangkuhl; D. J. Muller; Y. Ji; S. G. Leckband; J. S. Leeder; R. L. Graham; D. L. Chiulli; A. LLerena; T. C. Skaar; S. A. Scott; J. C. Stingl; T. E. Klein; K. E. Caudle; A. Gaedigk

doi:10.1002/cpt.147

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

J. K. Hicks, J. R. Bishop, K. Sangkuhl, D. J. Muller, Y. Ji, S. G. Leckband, J. S. Leeder, R. L. Graham, D. L. Chiulli, A. LLerena, T. C. Skaar, S. A. Scott, J. C. Stingl, T. E. Klein, K. E. Caudle, A. Gaedigk

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

717 Scopus citations

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

Original language	English (US)
Pages (from-to)	127-134
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	98
Issue number	2
DOIs	https://doi.org/10.1002/cpt.147
State	Published - Aug 1 2015

Bibliographical note

Publisher Copyright:
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Access

10.1002/cpt.147

OpenUrl availability

Full text

Cite this

Hicks, J. K., Bishop, J. R., Sangkuhl, K., Muller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R. L., Chiulli, D. L., LLerena, A., Skaar, T. C., Scott, S. A., Stingl, J. C., Klein, T. E., Caudle, K. E., & Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical pharmacology and therapeutics, 98(2), 127-134. https://doi.org/10.1002/cpt.147

Hicks, JK, Bishop, JR, Sangkuhl, K, Muller, DJ, Ji, Y, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, A, Skaar, TC, Scott, SA, Stingl, JC, Klein, TE, Caudle, KE & Gaedigk, A 2015, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors', Clinical pharmacology and therapeutics, vol. 98, no. 2, pp. 127-134. https://doi.org/10.1002/cpt.147

@article{afb3860aaab04021b6cb8cc3a17ce4df,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors",

abstract = "Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).",

author = "Hicks, {J. K.} and Bishop, {J. R.} and K. Sangkuhl and Muller, {D. J.} and Y. Ji and Leckband, {S. G.} and Leeder, {J. S.} and Graham, {R. L.} and Chiulli, {D. L.} and A. LLerena and Skaar, {T. C.} and Scott, {S. A.} and Stingl, {J. C.} and Klein, {T. E.} and Caudle, {K. E.} and A. Gaedigk",

note = "Publisher Copyright: {\textcopyright} 2015 American Society for Clinical Pharmacology and Therapeutics.",

year = "2015",

month = aug,

day = "1",

doi = "10.1002/cpt.147",

language = "English (US)",

volume = "98",

pages = "127--134",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

AU - Hicks, J. K.

AU - Bishop, J. R.

AU - Sangkuhl, K.

AU - Muller, D. J.

AU - Ji, Y.

AU - Leckband, S. G.

AU - Leeder, J. S.

AU - Graham, R. L.

AU - Chiulli, D. L.

AU - LLerena, A.

AU - Skaar, T. C.

AU - Scott, S. A.

AU - Stingl, J. C.

AU - Klein, T. E.

AU - Caudle, K. E.

AU - Gaedigk, A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

AB - Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84962294272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962294272&partnerID=8YFLogxK

U2 - 10.1002/cpt.147

DO - 10.1002/cpt.147

M3 - Article

C2 - 25974703

AN - SCOPUS:84962294272

SN - 0009-9236

VL - 98

SP - 127

EP - 134

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 2

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this